Capital Fund Management S.A. Makes New $931,000 Investment in Amphastar Pharmaceuticals, Inc. $AMPH

Capital Fund Management S.A. acquired a new stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 40,570 shares of the company’s stock, valued at approximately $931,000.

A number of other institutional investors have also recently made changes to their positions in the company. PNC Financial Services Group Inc. boosted its stake in Amphastar Pharmaceuticals by 13.8% during the first quarter. PNC Financial Services Group Inc. now owns 4,783 shares of the company’s stock valued at $139,000 after buying an additional 580 shares during the last quarter. Cynosure Group LLC raised its holdings in shares of Amphastar Pharmaceuticals by 62.8% during the 1st quarter. Cynosure Group LLC now owns 12,401 shares of the company’s stock worth $360,000 after acquiring an additional 4,783 shares in the last quarter. Nuveen LLC bought a new position in shares of Amphastar Pharmaceuticals during the 1st quarter valued at approximately $2,773,000. Public Sector Pension Investment Board grew its holdings in shares of Amphastar Pharmaceuticals by 27.2% in the first quarter. Public Sector Pension Investment Board now owns 118,885 shares of the company’s stock valued at $3,446,000 after purchasing an additional 25,455 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its position in Amphastar Pharmaceuticals by 950.0% in the first quarter. Russell Investments Group Ltd. now owns 2,058 shares of the company’s stock worth $60,000 after purchasing an additional 1,862 shares during the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Insider Buying and Selling

In other news, Director Richard K. Prins sold 4,179 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $27.10, for a total transaction of $113,250.90. Following the transaction, the director directly owned 35,183 shares in the company, valued at approximately $953,459.30. This trade represents a 10.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Floyd F. Petersen sold 16,679 shares of the business’s stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $26.49, for a total transaction of $441,826.71. Following the completion of the transaction, the director directly owned 75,531 shares of the company’s stock, valued at $2,000,816.19. This trade represents a 18.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 21,858 shares of company stock worth $581,313. Insiders own 27.50% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on AMPH. Bank of America increased their price objective on shares of Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research report on Tuesday, August 26th. Weiss Ratings restated a “hold (c)” rating on shares of Amphastar Pharmaceuticals in a report on Monday. Zacks Research downgraded shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, November 14th. Piper Sandler lowered their target price on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating for the company in a research note on Friday, August 8th. Finally, Needham & Company LLC reduced their price target on shares of Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Two investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $31.20.

Amphastar Pharmaceuticals Price Performance

AMPH opened at $26.77 on Friday. The company has a market capitalization of $1.23 billion, a price-to-earnings ratio of 11.85, a PEG ratio of 7.61 and a beta of 0.91. The company has a current ratio of 3.12, a quick ratio of 2.21 and a debt-to-equity ratio of 0.78. Amphastar Pharmaceuticals, Inc. has a 12-month low of $20.39 and a 12-month high of $45.39. The business’s fifty day simple moving average is $25.63 and its 200-day simple moving average is $25.61.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.10. Amphastar Pharmaceuticals had a return on equity of 19.70% and a net margin of 15.43%.The firm had revenue of $191.84 million during the quarter, compared to the consensus estimate of $186.90 million. On average, equities research analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.49 earnings per share for the current fiscal year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.